Originally announced in a press release issued on June 4, 2025, by RadNet, Inc. (NASDAQ: RDNT), a leading U.S.-based provider of diagnostic imaging services and digital health solutions.
RadNet has confirmed the acquisition of See-Mode Technologies PTE LTD, a global innovator in artificial intelligence (AI) for ultrasound imaging. The acquisition was completed through DeepHealth, RadNet’s wholly-owned digital health subsidiary. The move marks a significant expansion of RadNet's capabilities in AI-powered diagnostic imaging, particularly for ultrasound, and brings promising implications for healthcare systems across Europe.
See-Mode has developed advanced AI applications that assist in the detection and characterization of thyroid nodules and breast lesions. These tools not only enhance diagnostic accuracy but also support radiologists with standardized reporting and improved workflow efficiency. This is especially valuable in Europe, where demand for high-quality, cost-efficient diagnostic imaging continues to grow amid pressure on public health budgets and staffing shortages.
In initial deployments in RadNet’s U.S. facilities, See-Mode’s FDA-cleared thyroid ultrasound AI demonstrated up to a 30% reduction in scan time, driven by its automated detection and reporting functionality. This gain in efficiency could translate into improved patient access, faster diagnosis, and increased imaging capacity, offering clear benefits for European imaging providers aiming to optimize throughput and reduce wait times.
Dr. Howard Berger, CEO of RadNet, highlighted the growing clinical importance of AI in ultrasound: “Thyroid and breast cancers are among the most prevalent cancers globally, particularly affecting women. With more than 20 million ultrasound exams performed annually in the U.S. alone, there is enormous opportunity to improve consistency and efficiency. See-Mode’s AI addresses these pain points directly.”
For European healthcare systems prioritizing population health management, these innovations have the potential to strengthen early detection programms by enabling faster, more reliable screening workflows. By reducing scan time and standardizing reporting, AI-assisted ultrasound may allow more patients to be screened within the same timeframe, critical for expanding preventive care and reducing diagnostic delays in high-incidence conditions like breast and thyroid cancer.
Dr. Milad Mohammadzadeh, Co-Founder of See-Mode, added: “Ultrasound is inherently complex and user-dependent. Integrating our technology within DeepHealth and RadNet provides a unique opportunity to transform clinical workflows at scale.”
Kees Wesdorp, CEO of RadNet’s Digital Health division, emphasized the broader vision: “See-Mode’s technology will become an integral part of DeepHealth’s portfolio, which spans AI tools for breast, lung, prostate, and brain imaging. This acquisition lays the foundation for a new generation of AI-driven ultrasound solutions.”
RadNet and DeepHealth plan to commercialize these tools globally, making them accessible to third-party providers—including those in Europe—interested in harnessing AI to support radiologists, improve screening efficiency, and enable more proactive, data-driven approaches to population health.
